Precigen, Inc. (PGEN) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Precigen, Inc. on April 3, 2023. The filing discloses the entry into a Material Definitive Agreement with Alaunos Therapeutics ("Alaunos").
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics. The only specific financial obligation disclosed is an annual license fee of $75,000 to be paid by Alaunos to Precigen. No milestone payments or royalties are associated with this agreement.
Material Changes and Agreement Details
On April 3, 2023, Precigen entered into an amended and restated exclusive license agreement with Alaunos, replacing the October 5, 2018 agreement. Key terms include:
- Licenses Granted: Alaunos received an exclusive, worldwide, royalty-free, sub-licensable license for T-cell receptor (TCR) products targeting neoantigens for cancer and HPV-related cancer prevention. This also covers certain Sleeping Beauty technology patents for TCR products targeting both neoantigens and shared antigens.
- Non-Exclusive Rights: Alaunos was granted non-exclusive rights regarding shared antigens, NK cells, and gamma delta T-cells.
- Exclusions: Alaunos lost rights to Precigen's RheoSwitch gene switch (RTS) for IL-12 expression, CAR products (including CD-19 and BCMA), and Gorilla IL-12 Products. Precigen retains the right to develop these excluded products.
- Responsibilities: Alaunos is solely responsible for research, development, and commercialization of the licensed products with no diligence obligations.
- Restrictions: Precigen is restricted from using the licensed IP to develop exclusive cancer treatment products during the agreement term.
Outlook, Risks, and Contingencies
The agreement terminates on a product-by-product and/or country-by-country basis upon the expiration of the last patent claim. Alaunos may terminate on a country-by-country or program-by-program basis with written notice. Either party may terminate for material breach. The filing notes customary representations, warranties, indemnity, and confidentiality provisions but does not disclose specific litigation risks or unusual items beyond the restructuring of the partnership.
Investor Verification Checklist
- Verify the impact of the $75,000 annual fee on Precigen's future revenue projections.
- Confirm the status of Precigen's retained rights to RheoSwitch, CAR, and Gorilla IL-12 technologies.
- Review Alaunos' progress on the licensed T-cell receptor programs to assess the strategic value of the royalty-free arrangement.
- Check for any subsequent filings regarding the termination or further amendment of this agreement.